JP2020501577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501577A5 JP2020501577A5 JP2019533340A JP2019533340A JP2020501577A5 JP 2020501577 A5 JP2020501577 A5 JP 2020501577A5 JP 2019533340 A JP2019533340 A JP 2019533340A JP 2019533340 A JP2019533340 A JP 2019533340A JP 2020501577 A5 JP2020501577 A5 JP 2020501577A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- solution
- affinity ligand
- light chain
- stationary phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 6
- 230000005526 G1 to G0 transition Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Chemical group CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Chemical group C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- 230000004988 N-glycosylation Effects 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16205587 | 2016-12-21 | ||
| EP16205587.5 | 2016-12-21 | ||
| EP17157002 | 2017-02-20 | ||
| EP17157002.1 | 2017-02-20 | ||
| PCT/EP2017/083429 WO2018114877A1 (en) | 2016-12-21 | 2017-12-19 | In vitro glycoengineering of antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501577A JP2020501577A (ja) | 2020-01-23 |
| JP2020501577A5 true JP2020501577A5 (cg-RX-API-DMAC7.html) | 2021-01-07 |
| JP6850351B2 JP6850351B2 (ja) | 2021-03-31 |
Family
ID=60997429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533340A Active JP6850351B2 (ja) | 2016-12-21 | 2017-12-19 | 抗体のインビトロ糖鎖工学 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200165320A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3559248B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6850351B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102317884B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN110088291A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017384276B9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3044920C (cg-RX-API-DMAC7.html) |
| IL (1) | IL267351A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019006266A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI780097B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018114877A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017381657B2 (en) * | 2016-12-21 | 2020-07-23 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
| CN110100007B (zh) | 2016-12-21 | 2024-05-28 | 豪夫迈·罗氏有限公司 | 用于体外糖工程化抗体的酶的再使用 |
| AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
| KR20210031932A (ko) | 2018-07-13 | 2021-03-23 | 젠맵 에이/에스 | Cd38 항체의 변이체 및 그의 용도 |
| MA53123A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
| PE20230113A1 (es) | 2020-01-16 | 2023-01-27 | Genmab As | Formulaciones de anticuerpos anti-cd38 y usos de las mismas |
| EP4399227A1 (en) | 2021-09-06 | 2024-07-17 | Genmab A/S | Antibodies capable of binding to cd27, variants thereof and uses thereof |
| AU2024271605A1 (en) | 2023-05-12 | 2025-11-13 | BioNTech SE | Antibodies capable of binding to ox40, variants thereof and uses thereof |
| WO2025049881A1 (en) * | 2023-09-01 | 2025-03-06 | Catalent Pharma Solutions, Llc | Dnase co-expression in host cells |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| WO1992016640A1 (en) | 1991-03-18 | 1992-10-01 | The Scripps Research Institute | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AU5874798A (en) | 1997-01-31 | 1998-08-25 | Biovation Limited | Vaccination methods and molecules |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP1460425A1 (en) * | 2003-03-17 | 2004-09-22 | Boehringer Mannheim Gmbh | Deglycosylated enzymes for conjugates |
| BRPI0508761A (pt) | 2004-03-31 | 2007-08-14 | Genentech Inc | anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20070266448A1 (en) | 2006-05-11 | 2007-11-15 | Alexander Lifke | Method for the production of antibodies |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| JP2010536355A (ja) * | 2007-08-31 | 2010-12-02 | エフ．ホフマン−ラ ロシュ アーゲー | グリコシル化プロファイル分析 |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| CN102369215B (zh) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| BRPI1007602A2 (pt) | 2009-05-27 | 2016-02-16 | Hoffmann La Roche | "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia" |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| CN102471376A (zh) | 2009-07-30 | 2012-05-23 | 弗·哈夫曼-拉罗切有限公司 | 酶促抗体加工 |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| WO2012037407A1 (en) | 2010-09-17 | 2012-03-22 | Prozyme, Inc. | Isolation and deglycosylation of glycoproteins |
| EP2768857B1 (en) * | 2011-10-19 | 2020-01-01 | NovImmune SA | Methods of purifying antibodies |
| JP6282232B2 (ja) * | 2012-02-10 | 2018-02-21 | ユニバーシティー オブ メリーランド，ボルティモア | 抗体及びそのＦｃフラグメントの酵素化学的糖鎖改変 |
| US20170051328A1 (en) | 2014-02-18 | 2017-02-23 | The University Of Manitoba | Methods to produce single glycoform antibodies |
| WO2016037947A1 (en) | 2014-09-10 | 2016-03-17 | F. Hoffmann-La Roche Ag | Galactoengineered immunoglobulin 1 antibodies |
| AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
-
2017
- 2017-12-19 AU AU2017384276A patent/AU2017384276B9/en active Active
- 2017-12-19 WO PCT/EP2017/083429 patent/WO2018114877A1/en not_active Ceased
- 2017-12-19 EP EP17829955.8A patent/EP3559248B2/en active Active
- 2017-12-19 CN CN201780079057.7A patent/CN110088291A/zh active Pending
- 2017-12-19 JP JP2019533340A patent/JP6850351B2/ja active Active
- 2017-12-19 CA CA3044920A patent/CA3044920C/en active Active
- 2017-12-19 MX MX2019006266A patent/MX2019006266A/es unknown
- 2017-12-19 CN CN202411870260.4A patent/CN119685431A/zh active Pending
- 2017-12-19 KR KR1020197017701A patent/KR102317884B1/ko active Active
- 2017-12-20 TW TW106144931A patent/TWI780097B/zh active
-
2019
- 2019-06-13 IL IL267351A patent/IL267351A/en unknown
- 2019-06-20 US US16/447,093 patent/US20200165320A1/en not_active Abandoned
-
2023
- 2023-05-16 US US18/318,487 patent/US20240101643A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501577A5 (cg-RX-API-DMAC7.html) | ||
| Huhn et al. | IgG glycosylation analysis | |
| Mahan et al. | A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis | |
| TWI670279B (zh) | 抗體純化及純度監測 | |
| JP6419844B2 (ja) | Ｃｙｓ連結された抗体−薬物コンジュゲートの精製方法 | |
| CN106604930B (zh) | 去糖基化试剂和方法 | |
| US12157756B2 (en) | Detection and quantification of glycosylated peptides | |
| AU2015289045A1 (en) | Improved method of mapping glycans of glycoproteins in serum samples | |
| EP2394173A2 (en) | Immunoglobulin glycosylation pattern analysis | |
| EP3196646B1 (en) | Methods of mapping protein variants | |
| JP2022551756A (ja) | 宿主細胞タンパク質を特徴付けるための方法 | |
| Tayi et al. | Isolation and quantification of N-glycans from immunoglobulin G antibodies for quantitative glycosylation analysis | |
| JP2016513643A (ja) | 漏出したアフィニティ精製リガンドの除去 | |
| KR20210148349A (ko) | 크로마토그래피 수지의 재생 방법 | |
| Bodnar et al. | An integrated approach to analyze EG2-hFc monoclonal antibody N-glycosylation by MALDI-MS | |
| WO2012015028A1 (ja) | 抗体の糖鎖を調製する方法 | |
| JP7673905B2 (ja) | 左右非対称の糖鎖を有する抗体を均一に含む抗体集団、及びその製造方法 | |
| JP2025510508A (ja) | 宿主細胞タンパク質を特徴付けるためのサイズ排除クロマトグラフィ | |
| TWI902667B (zh) | 醣基化肽之偵測及定量 | |
| Bresolin et al. | Purification of anti-interleukin-6 monoclonal antibody using precipitation and immobilized metal-ion affinity chromatography | |
| WO2018186063A1 (ja) | 糖鎖を調製する方法 | |
| Plavša et al. | N-Glycans of Both Fc and Fab Regions of IgG are Changed in Children with Type 1 Diabetes | |
| Kubota | Studies on Quality Evaluation of Biopharmaceuticals by Chromatographic and Electrophoretic Techniques | |
| HK40044470B (en) | Detection and quantification of glycosylated peptides | |
| HK40044470A (en) | Detection and quantification of glycosylated peptides |